First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
Journal
Cancer Immunology, Immunotherapy
Journal Volume
71
Journal Issue
2
Pages
417-431
Date Issued
2022
Author(s)
Italiano A.
Cassier P.A.
Alanko T.
Peltola K.J.
Gazzah A.
Shiah H.-S.
Calvo E.
Cervantes A.
Roda D.
Tosi D.
Gao B.
Millward M.
Warburton L.
Tanner M.
Englert S.
Lambert S.
Parikh A.
Afar D.E.
Vosganian G.
Moreno V.
SDGs
Publisher
Springer Science and Business Media Deutschland GmbH
Type
journal article